Shield Therapeutics Plc

As of June 30, 2026, Shield Therapeutics Plc carries a market capitalization of 6.63B, placing it among publicly traded companies globally. Its enterprise value stands at 8.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shield Therapeutics Plc's next confirmed earnings release is scheduled for April 29, 2027.

As of June 30, 2026, Shield Therapeutics Plc has 1.07B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shield Therapeutics Plc maintains a current ratio of 0.75, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 23, 2026, Shield Therapeutics Plc's stock has declined approximately 29.61% over the past 52 weeks. The 50-day moving average sits at 5.19, while the 200-day moving average is 7.14.

As of June 30, 2026, Shield Therapeutics Plc holds 629.26M in cash and equivalents against 2.11B in total debt, resulting in a net debt position of 1.48B. Total book value stands at -1.28B, with working capital of -859.70M providing operational flexibility.

Shield Therapeutics Plc's most recent stock split took place on December 16, 2022 with a 34:35 split ratio.